The Danish biotech company, TopoTarget A/S, said that it has appointed Anders Fink Vadsholt as its new chief financial officer and head of investor relations, effective 15 April 2010. The appointment comes as the company looks to streamline its organisation in order to focus on the commercialisation of belinostat, its lead cancer drug. Mr Vadsholt was, most recently, a partner at BankInvest Biomedical Venture, where he was responsible for that company’s investment in TopoTarget. Prior to that, he was the CFO of a number of smaller biotech companies, including 7TM Pharma, which he also co-founded.
Copyright 2010 Evernow Publishing